磺胺多辛
| 中文名稱 | 磺胺多辛 |
|---|---|
| 中文同義詞 | 磺胺二甲異惡唑;硫胺多辛;磺胺鄰二甲氧嘧啶/磺胺多辛;磺胺多辛 周效磺胺;周效磺胺(磺胺多辛);磺胺鄰二甲氧嘧啶;周效磺胺;磺胺鄰二甲氧嘧啶 (SDX)溶液, 100PPM |
| 英文名稱 | Sulfadoxine |
| 英文同義詞 | 4-amino-n-(5,6-dimethoxy-4-pyrimidinyl)-benzenesulfonamid;6-(4-aminobenzenesulfonamido)-4,5-dimethoxypyrimidine;fanasil;sulforthomidine;6-(4-aminobenzenesulfonamide)-4,5-dimethoxypyrimidine;Sulfadoxine BP2000/USP25;Sulphadoxine BP98;Fansidar (suldfadoxine and pyrimethamine) |
| CAS號 | 2447-57-6 |
| 分子式 | C12H14N4O4S |
| 分子量 | 310.33 |
| EINECS號 | 219-504-9 |
| 相關(guān)類別 | 磺胺類;代謝組學(xué);醫(yī)藥原料;抗生素;生命科學(xué)標(biāo)準(zhǔn)品;代謝途徑;小分子抑制劑;醫(yī)藥中間體;醫(yī)藥化工類;Miscellaneous Natural Products;Chemical Structure;OthersAlphabetic;Principle;S;SN - SZ;化合物:原料藥;生化試劑;原料;合成抗菌藥;醫(yī)藥原料藥;醫(yī)用原料;醫(yī)藥、農(nóng)藥及染料中間體;化工中間體;日用化學(xué)品;其他類;化藥雜質(zhì)-磺胺多辛;工業(yè)化;Intermediates & Fine Chemicals;Pharmaceuticals;Antibiotics;BacteriostaticAntibiotics;Amines;Aromatics;Sulfur & Selenium Compounds;Pharmaceutical intermediate;API;FANASIL |
| Mol文件 | 2447-57-6.mol |
| 結(jié)構(gòu)式 | ![]() |
磺胺多辛 性質(zhì)
| 熔點 | 190-194°C |
|---|---|
| 沸點 | 298°C (rough estimate) |
| 密度 | 1.4006 (rough estimate) |
| 折射率 | 1.6270 (estimate) |
| 儲存條件 | Keep in dark place,Inert atmosphere,Room temperature |
| 溶解度 | 溶于乙醇&20mg/ml的氫氧化銨(9:1) |
| 形態(tài) | 粉末 |
| 酸度系數(shù)(pKa) | 6.16±0.50(Predicted) |
| 顏色 | 白色 |
| 水溶解性 | 209.8mg/L(temperature not stated) |
| Merck | 14,8906 |
| BRN | 625453 |
| BCS Class | 3/1 |
| 主要應(yīng)用 | 臨床測試 |
| InChI | 1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16) |
| InChIKey | PJSFRIWCGOHTNF-UHFFFAOYSA-N |
| SMILES | COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC |
周效磺胺別名周效磺胺,磺胺多辛,磺胺鄰二甲氧嘧啶。其是一種白色或類白色結(jié)晶粉末。其主要用于氣管炎、肺炎、菌痢、尿路感染、皮膚軟組織感染及預(yù)防風(fēng)濕熱等。
周效磺胺一般用于炎癥的治療, 如上呼吸道感染扁桃體炎、菌痢腸炎、皮膚感染等,還可與其他藥物配合,用于治療肺結(jié)核、 淋巴結(jié)核。Sulfadoxine (Sulphadoxine) 是一種超長效磺胺類藥物,作用于P. Vivax,IC50為249 μg/ml。Sulfadoxine(Sulphadoxine) is an ultra-long-lasting sulfonamide. Sulfadoxine is often used in combination with pyrimethamine to treat or prevent malaria. Both drugs are antifolates; they inhibit the production of enzymes involved in the synthesis of folic acid within the parasites. Either drug by itself is only moderately effective in treating malaria, because the parasite Plasmodium falciparum may be able to use exogenous folic acid, i.e. folic acid which is present in the parasite's environment, while in combination, the two substances have a synergistic effect which outbalances that ability [1, 2].
安全信息
| 提供商 | 語言 |
|---|---|
|
英文
|
